LDL cholesterol (LDL - c) and non-HDL cholesterol (non-HDL-c) are prognostic factors of cardiovascular risk. However, their validity as trial-level surrogates for cardiovascular outcomes is debated. This study aimed to determine whether LDL - c and non-HDL-c are reliable surrogates for cardiovascular events in statin trials, and to explore discrepancies in previous studies. We conducted an umbrella review of meta-analyses of randomized controlled trials (RCTs) assessing statin efficacy versus placebo or usual care on all-cause mortality and cardiovascular events. We search studies published between 1987 and August 2023 from PubMed, Embase, and the Cochrane Library. Baseline lipid levels, absolute risk differences (ARDs), and hazard ratios or risk ratios (RRs) for major cardiovascular events and all-cause or cardiovascular mortality were analysed. Weighted linear regressions between log RR or ARD, and absolute difference in non-HDL-c or LDL - c were performed. The coefficients of determination (R2trial) were calculated, with their 95% CI computed through bootstrapping. The surrogate threshold effect (STE) was also estimated. Twenty RCTs and 194 686 participants were included, with a median follow-up of 4.85 years. Statin treatment showed significant efficacy in improving all clinical outcomes. However, the association between treatment effects on LDL - c or non-HDL-c reduction and clinical outcomes was weak. The R²trial were ranging from 0 to 0.1 for LDL - c, and from 0 to 0.04 for non-HDL-c. The STE for major adverse cardiovascular event was 0.76 (0.36–1.69) mmol/L for LDL - c, and 0.87 (0.49–2.19) mmol/L for non-HDL-c. Neither LDL - c nor non-HDL-c demonstrated trial-level surrogacy for predicting treatment effects on mortality and cardiovascular events in statin trials. Although they are relevant biomarkers for the follow-up of patients treated with statins, their reduction does not reliably predict a similar reduction in cardiovascular risk. As such, they should not be used as pivotal evidence in drug trials.
Introduction: Artificial intelligence (AI) is increasingly integrated into healthcare, reshaping clinical decision-making and care pathways. In solid organ transplantation (SOT), where clinical complexity and uncertainty are high, AI holds particular promise. Yet, beyond technical performance, its successful adoption depends on how it is understood and perceived by patients and healthcare professionals (HP). To date, little is known about these perspectives in SOT. This study provides the first assessment of knowledge and perceptions of AI among patients and healthcare professionals in this field. Methods: A cross-sectional study was conducted among SOT patients and HP. Patients were recruited through associations, and HP through the French Society of Transplantation. Data were collected using a web-based questionnaire including open-ended and closed items addressing sociodemographic characteristics, declared knowledge, and perception of AI and its applications in healthcare and SOT. Thematic coding was used for qualitative data, regression models for association analyses, and reliability testing was assessed (Cronbach's α > 0.7). Results: 218 patients and 92 HP participated. Patients reported low AI declared knowledge (mean 2.4/10), while HP suggested slightly higher levels (3.8/10). 140 patients had heard of AI in healthcare, and very few were aware of its use in SOT ( n = 20). Although most HP were familiar with AI in healthcare ( n = 71), declared knowledge of AI applications in SOT remained limited ( n = 39). Overall, both groups expressed positive perceptions of AI in SOT, with concerns mainly related to dehumanization of care and potential errors. Patients largely viewed AI as a complement too, rather than a replacement for healthcare professionals. Discussion: As declared knowledge was associated with perceptions of AI, these findings highlight the importance of targeted educational interventions to promote informed integration of AI in SOT. This exploratory study provides valuable insights into potential facilitators and barriers to adoption, providing actionable insights to guide implementation strategies and policy development in transplant care.
The use of Connected Medical Devices (CMDs) is growing significantly throughout the world. Although they are not dispensed in pharmacies and are not part of the pharmacy-only drug dispensing system, clinical pharmacists must be able to support patients in the use of these new technologies, which are central to their care. The aim of this study is to identify the role of the community pharmacist in supporting patients who use CMDs, using the case of connected watches in electrophysiology. Semi-structured interviews were conducted between 15 February and 20 April 2024 by a pharmacy student. The questionnaires were drafted in collaboration with a pharmacist, a cardiac electrophysiologist, a methodologist specializing in the evaluation of medical devices, and an ethical philosopher specializing in the support and acceptability of new technologies. The aim of these questionnaires was to study the use of connected watches and support for patients who own them. A total of 4 cardiac electrophysiologists and 10 cardiac electrophysiology patients were interviewed, and then 6 pharmacists were also questioned about the roles identified by physicians and patients. This study identified a major need on the part of specialist physicians for clinical pharmacist support in helping patients use connected watches. Patients expressed a high level of confidence in their pharmacists to support them, and in the motivation of pharmacists’ ability to take up these challenges. A number of challenges remain, such as the effective integration of this support into pharmacy practice, remuneration, and the organization of collaboration between clinical pharmacists and hospital electrophysiologists.